ClinicalTrials.gg
TerminatedNCT02109445Updated Jan 10, 2019Results posted

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

A Phase 2 interventional study of PF-03084014 and Gemcitabine in Metastatic Cancer Pancreas, sponsored by Pfizer. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-10.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated on 24JUN15 due to change in strategy of PF-03084014 development.No safety/efficacy concerns were behind the reason of trial termination

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Pancreatic Neoplasms by Pfizer — 3 open to participants now, 4 under way, 1 of them phase 3. Pancreatic Neoplasms · Pfizer.

Enrollment
24th of 24
3 · median 79
Started
2014
the only one that year
Phase 2
7 of 25
none open now
Registered
13th of 25
by date

Among the 25 studies in Pancreatic Neoplasms by Pfizer, this one is the 24th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2014, is one of 7 in phase 2, and was the 13th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,002 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

3 of the 25 studies in Pancreatic Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 742 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Pancreatic Neoplasms by Pfizer, or all of them as a file.
02

Study summary

This study consists of a Phase 1b portion aimed to determine the maximum tolerated dose and the safety profile of PF-03084014 in combination with gemcitabine and nab-paclitaxel followed by a Phase 2 portion to evaluate the efficacy of the triple combination in terms of overall survival in patients with metastatic pancreatic ductal adenocarcinoma not previously treated with anticancer therapies.

03

Conditions studied

  • Metastatic Cancer Pancreas
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically or cytologically diagnosis of ductal adenocarcinoma of the pancreas.
  • No prior radiotherapy, surgery chemotherapy or therapy for metastatic disease. Prior therapy with 5-FU or gemcitabine (± gemcitabine post radiation) administered as radiosensitizer allowed, provided at least 6 months have elapsed between the last dose and study registration
  • Tumor tissue available (Archival 6 months old or de novo )
  • as per 1.1
  • Performance Status () 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Symptomatic requiring
  • Prior therapy with gamma secretase inhibitors or other Notch pathway inhibitor
  • Major surgery within 4 weeks of registration in the current study
  • Known to gemcitabine or nab-paclitaxel or any of the
  • Current or anticipated need for food or drugs that are strong/moderate inhibitors or inducers
  • Diagnosis of any second within 3 years prior to registration
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Phase 1

    PF-03084014 in combination with gemcitabine and nab-paclitaxel

    Drug: PF-03084014 · Drug: Gemcitabine · Drug: Nab-paclitaxel

  • Experimental
    Phase 2 Arm A

    PF-03084014 in combination with gemcitabine and nab-paclitaxel

    Drug: PF-03084014 · Drug: Gemcitabine · Drug: Nab-paclitaxel

  • Active comparator
    Phase 2 Arm B

    Gemcitabine plus nab-Paclitaxel

    Drug: Gemcitabine · Drug: Nab-paclitaxel

Interventions

  • Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID

  • Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.

  • Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.

    Also known as: Abraxane

  • Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.

  • Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.

  • Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.

    Also known as: Abraxane

  • Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.

  • Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.

    Also known as: Abraxane

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1

    DLT was defined as any of the following events occurring during the first cycle of treatment and considered at least possibly-related to study medication: any Grade 3 or 4 clinically-relevant non-hematologic and/or hematologic toxicity, delay of more than 2 weeks in receiving the next scheduled cycle due to persisting treatment-related toxicities.

    Time frame: Cycle 1 (28 days)

  2. Overall Survival (OS) in Phase 2

    Overall survival was the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact.

    Time frame: From start of study treatment, collected every 3 months until death (up to 5 years)

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) by Seriousness and Relationship to Treatment in Phase 1

    Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. Severity was graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). Grade 1=mild, Grade 2=moderate, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=life-threatening.

    Time frame: Baseline up to 28-35 days post last administration of study drug

  2. Number of Participants With Adverse Events (AEs) by Seriousness and Relationship to Treatment in Phase 2

    Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. Severity was graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). Grade 1=mild, Grade 2=moderate, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=life-threatening.

    Time frame: Baseline up to 28-35 days post last administration of study drug

  3. Number of Participants With Laboratory Abnormalities in Phase 1

    Following parameters were analyzed for laboratory examination: hematology (hemoglobin, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (urea, creatinine, glucose, calcium, sodium, potassium, chloride, magnesium, phosphate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid); urinalysis (protein, blood, microscopy\[if urine tested positive for blood or protein\]).

    Time frame: Screening; Cycle 1 Days 1, 8, 15, 22; up to 28-35 days post last administration of study drug

  4. Number of Participants With Laboratory Abnormalities in Phase 2

    Following parameters were analyzed for laboratory examination: hematology (hemoglobin, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (urea, creatinine, glucose, calcium, sodium, potassium, chloride, magnesium, phosphate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid); urinalysis (protein, blood, microscopy\[if urine tested positive for blood or protein\]).

    Time frame: Screening; Days 1, 8, 15 of each cycle; up to 28-35 days post last administration of study drug

  5. Number of Participants With Clinically Significant Change From Baseline in Vital Signs at Phases 1 and 2

    Following parameters were analyzed for examination of vital signs: systolic and diastolic blood pressure, heart rate, weight and body surface area.

    Time frame: Baseline up to 28-35 days after treatment discontinuation

  6. Number of Participants With Worsening QTc Results in Phase 1

    Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) were corrected for heart rate (QTc) using Fridericia (QTcF) and Bazett (QTcB) formulas. Any change from baseline in QTc was considered as worsening in ECG and was classified accordingly to the Common Terminology Criteria (CTC) grade. Grading was as follows: prolonged QTc of 450 to 480 milliseconds (msec)=Grade 1, 481 to 500 msec=Grade 2, more than or equal to (\>=) 501 msec on at least 2 seperate ECGs=Grade 3, \>=501 or more than (\>) 60 msec change from baseline and Torsade de pointes or polymorphic ventricular tachycardia or signs of serious arrhythmia=Grade 4.

    Time frame: Screening, Cycle 1 Days 3 and 22, Cycles 2 and 3 Day 1, end of treatment

  7. Number of Participants With Worsening QTc Results in Phase 2

    Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) were corrected for heart rate (QTc) using Fridericia (QTcF) and Bazett (QTcB) formulas. Any change from baseline in QTc was considered as worsening in ECG and was classified accordingly to the Common Terminology Criteria (CTC) grade. Grading was as follows: prolonged QTc of 450 to 480 milliseconds (msec)=Grade 1, 481 to 500 msec=Grade 2, more than or equal to (\>=) 501 msec on at least 2 seperate ECGs=Grade 3, \>=501 or more than (\>) 60 msec change from baseline and Torsade de pointes or polymorphic ventricular tachycardia or signs of serious arrhythmia=Grade 4.

    Time frame: Screening, Cycle 1 Days 1 and 22, Cycles 2 and 3 Day 1, end of treatment

  8. Area Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 1

    AUC included AUC from time 0 extrapolated to infinite time (AUCinf), AUC from time 0 to end of dosing interval (AUCtau, tau=12 hours), and AUC from time 0 to last measured concentration (AUClast).

    Time frame: PF-03084014: Cycle 1 Days 3, 15, 22; Day 1 of subsequent cycles; and end of treatment. nab-P: Cycle 1 Days 1-3 and 15-17. Gemcitabine: Cycle 1 Days 1 and 15.

  9. Area Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 2

    AUC included AUC from time 0 extrapolated to infinite time (AUCinf), AUC from time 0 to end of dosing interval (AUCtau), and AUC from time 0 to last measured concentration (AUClast).

    Time frame: Cycle 1 Day 1 till end of last cycle

  10. Maximum Observed Plasma Concentration (Cmax) for PF-03084014, Nab-P and GEM in Phase 1

    Time frame: PF-03084014: Cycle 1 Days 3, 15, 22; Day 1 of subsequent cycles; and end of treatment. nab-P: Cycle 1 Days 1-3 and 15-17. Gemcitabine: Cycle 1 Days 1 and 15.

  11. Maximum Observed Plasma Concentration (Cmax) for PF-03084014, Nab-P and GEM in Phase 2

    Time frame: Cycle 1 Day 1 till end of last cycle

  12. Systemic Clearance (CL) of Nab-paclitaxel in Phase 1

    Time frame: Cycle 1 Days 1-3, and 15-17

  13. Systemic Clearance (CL) of Gemcitabine in Phase 1

    Time frame: Cycle 1 Days 1 and 15

  14. Systemic Clearance (CL) of PF-03084014, Nab-P and GEM in Phase 2

    Time frame: Cycle 1 Day 1 till end of last cycle

  15. Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-03084014, Nab-P and GEM in Phase 1

    Time frame: PF-03084014: Cycle 1 Days 3, 15, 22; Day 1 of subsequent cycles; and end of treatment. nab-P: Cycle 1 Days 1-3 and 15-17. Gemcitabine: Cycle 1 Days 1 and 15.

  16. Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-03084014, Nab-P and GEM in Phase 2

    Time frame: Cycle 1 Day 1 till end of last cycle

  17. Volume of Distribution at Steady State (Vss) for Nab-P and GEM in Phase 1

    Time frame: Cycle 1 (Days 1 and 15 for gemcitabine; Days 1-3 and 15-17 for nab-paclitaxel)

  18. Volume of Distribution at Steady State (Vss) for PF-03084014, Nab-P and GEM in Phase 2

    Time frame: Cycle 1 Day 1 till end of last cycle

  19. Plasma Decay Half-life (t1/2) for Nab-P and GEM in Phase 1

    Time frame: Cycle 1 (Days 1 and 15 for gemcitabine; Days 1-3 and 15-17 for nab-paclitaxel)

  20. Plasma Decay Half-life (t1/2) for PF-03084014, Nab-P and GEM in Phase 2

    Time frame: Cycle 1 Day 1 till end of last cycle

  21. Number of Participants With Objective Response (OR) in Phase 1

    Number of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than (\<) 10 mm). No new lesions. PR was defined as more than or equal to (\>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: Screening till 28-35 days post last administration of study drug

  22. Number of Participants With Objective Response (OR) in Phase 2

    Number of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than (\<) 10 mm). No new lesions. PR was defined as more than or equal to (\>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: Screening till 28-35 days post last administration of study drug

  23. Duration of Response (DR) for Phases 1 and 2

    Duration of response (DR) defined as the difference in days between the first date criteria for progression occurred or the participant died due to any cause and the first date that criteria for a PR or CR were met. DR calculated as (months) = (progression/death date - first date of OR + 1) divided by 30.4. CR: disappearance of all target lesions. PR: at least 30% decrease in the sum of diameters of target lesions.

    Time frame: Baseline, every 8 weeks until disease progression or unacceptable toxicity (up to 5 years)

  24. 1-year and 2-year OS in Phase 2

    Overall survival was the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact.

    Time frame: From start of study treatment, collected every 3 months until death (up to 5 years)

  25. Progression-free Survival (PFS) in Phase 2

    PFS was defined as the time from the date of first dose to the date of the first documentation of objective tumor progression or death on study due to any cause, whichever occurred first. PFS (in months) was calculated as (first event date - date of randomization +1) divided by 30.4.

    Time frame: From start of study treatment, collected every 3 months until death (up to 5 years)

  26. Brief Pain Inventory-Short Form (BPI-sf) Score - Phase 2

    BPI-sf is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions. BPI-sf are 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each question is answered on a scale ranging from 0 to 10; '0=No pain and 10=Pain as bad as you can imagine'. Measure can be scored by item, with lower scores being indicative of less pain or pain interference.

    Time frame: Day 1 of Cycle 1 and subsequent cycles; end of treatment

  27. Change From Baseline in European Quality of Life Questionnaire (EQ-5D) - Phase 2

    EQ-5D: 6-item participant rated questionnaire to assess health-related quality of life in terms of a single utility score. There were 2 components: a Health State Profile and a Visual Analog Scale. Published weights are available that allow for the creation of a single summary score. Overall scores range from 0-1, with low scores representing a higher level of dysfunction.

    Time frame: Baseline till end of treatment

  28. European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire (EORTC QLQ-C30) - Phase 2

    EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.

    Time frame: Baseline till end of treatment

07

Results

Posted Jun 12, 2017
Limitations and caveats
Due to early termination of the study, only 3 participants were enrolled. Phase 2 was not carried out. As such, there is limited data for Phase 1 and no data for Phase 2.

Participant flow

The study planned to include 2 phases: Phase 1 (dose-finding phase) followed by Phase 2 (randomized phase). Due to early termination of the study, only 3 participants were enrolled in Phase 1 and Phase 2 was not conducted.

Participant flow — Overall Study
MilestonePF-03084014+Nab-Paclitaxel+Gemcitabine
Started3
Completed0
Not completed3
Withdrew: Symptomatic deterioration2
Withdrew: Adverse event1

Outcome measures

PrimaryNumber of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1

DLT was defined as any of the following events occurring during the first cycle of treatment and considered at least possibly-related to study medication: any Grade 3 or 4 clinically-relevant non-hematologic and/or hematologic toxicity, delay of more than 2 weeks in receiving the next scheduled cycle due to persisting treatment-related toxicities.

Time frame:
Cycle 1 (28 days)
Reported as:
Number · participants
Number of Participants With Dose-limiting Toxicities (DLTs) in Cycle 1
participantsPF-03084014 + Nab-Paclitaxel + Gemcitabine
Number of Participants With Dose-limiting Toxicities (DLTs) in Cycle 12
PrimaryOverall Survival (OS) in Phase 2

Overall survival was the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact.

Time frame:
From start of study treatment, collected every 3 months until death (up to 5 years)

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events (AEs) by Seriousness and Relationship to Treatment in Phase 1

Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. Severity was graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). Grade 1=mild, Grade 2=moderate, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=life-threatening.

Time frame:
Baseline up to 28-35 days post last administration of study drug
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) by Seriousness and Relationship to Treatment in Phase 1
participantsPF-03084014 + Nab-Paclitaxel + Gemcitabine
All-causality TEAEs3
Treatment-related TEAEs3
Grade 3 or 4 TEAEs3
SecondaryNumber of Participants With Adverse Events (AEs) by Seriousness and Relationship to Treatment in Phase 2

Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to study drug was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category. Severity was graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). Grade 1=mild, Grade 2=moderate, Grade 3=Severe or medically significant but not immediately life-threatening, Grade 4=life-threatening.

Time frame:
Baseline up to 28-35 days post last administration of study drug

No measurements were reported for this outcome.

SecondaryNumber of Participants With Laboratory Abnormalities in Phase 1

Following parameters were analyzed for laboratory examination: hematology (hemoglobin, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (urea, creatinine, glucose, calcium, sodium, potassium, chloride, magnesium, phosphate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid); urinalysis (protein, blood, microscopy\[if urine tested positive for blood or protein\]).

Time frame:
Screening; Cycle 1 Days 1, 8, 15, 22; up to 28-35 days post last administration of study drug
Reported as:
Number · participants
Number of Participants With Laboratory Abnormalities in Phase 1
participantsPF-03084014 + Nab-Paclitaxel + Gemcitabine
Number of Participants With Laboratory Abnormalities in Phase 13
SecondaryNumber of Participants With Laboratory Abnormalities in Phase 2

Following parameters were analyzed for laboratory examination: hematology (hemoglobin, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (urea, creatinine, glucose, calcium, sodium, potassium, chloride, magnesium, phosphate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid); urinalysis (protein, blood, microscopy\[if urine tested positive for blood or protein\]).

Time frame:
Screening; Days 1, 8, 15 of each cycle; up to 28-35 days post last administration of study drug

No measurements were reported for this outcome.

SecondaryNumber of Participants With Clinically Significant Change From Baseline in Vital Signs at Phases 1 and 2

Following parameters were analyzed for examination of vital signs: systolic and diastolic blood pressure, heart rate, weight and body surface area.

Time frame:
Baseline up to 28-35 days after treatment discontinuation

No measurements were reported for this outcome.

SecondaryNumber of Participants With Worsening QTc Results in Phase 1

Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) were corrected for heart rate (QTc) using Fridericia (QTcF) and Bazett (QTcB) formulas. Any change from baseline in QTc was considered as worsening in ECG and was classified accordingly to the Common Terminology Criteria (CTC) grade. Grading was as follows: prolonged QTc of 450 to 480 milliseconds (msec)=Grade 1, 481 to 500 msec=Grade 2, more than or equal to (\>=) 501 msec on at least 2 seperate ECGs=Grade 3, \>=501 or more than (\>) 60 msec change from baseline and Torsade de pointes or polymorphic ventricular tachycardia or signs of serious arrhythmia=Grade 4.

Time frame:
Screening, Cycle 1 Days 3 and 22, Cycles 2 and 3 Day 1, end of treatment
Reported as:
Number · participants
Number of Participants With Worsening QTc Results in Phase 1
participantsPF-03084014 + Nab-Paclitaxel + Gemcitabine
Number of Participants With Worsening QTc Results in Phase 1NA
SecondaryNumber of Participants With Worsening QTc Results in Phase 2

Triplicate 12-lead electrocardiogram (ECG) measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) were corrected for heart rate (QTc) using Fridericia (QTcF) and Bazett (QTcB) formulas. Any change from baseline in QTc was considered as worsening in ECG and was classified accordingly to the Common Terminology Criteria (CTC) grade. Grading was as follows: prolonged QTc of 450 to 480 milliseconds (msec)=Grade 1, 481 to 500 msec=Grade 2, more than or equal to (\>=) 501 msec on at least 2 seperate ECGs=Grade 3, \>=501 or more than (\>) 60 msec change from baseline and Torsade de pointes or polymorphic ventricular tachycardia or signs of serious arrhythmia=Grade 4.

Time frame:
Screening, Cycle 1 Days 1 and 22, Cycles 2 and 3 Day 1, end of treatment

No measurements were reported for this outcome.

SecondaryArea Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 1

AUC included AUC from time 0 extrapolated to infinite time (AUCinf), AUC from time 0 to end of dosing interval (AUCtau, tau=12 hours), and AUC from time 0 to last measured concentration (AUClast).

Time frame:
PF-03084014: Cycle 1 Days 3, 15, 22; Day 1 of subsequent cycles; and end of treatment. nab-P: Cycle 1 Days 1-3 and 15-17. Gemcitabine: Cycle 1 Days 1 and 15.
Reported as:
Geometric mean · nanogram*hour/milliliter (ng*hr/mL)
Area Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 1
nanogram*hour/milliliter (ng*hr/mL)PF-03084014 + Nab-Paclitaxel + Gemcitabine
AUClast for PF-03084014 on Day 3 (n=3)1122 ± 913
AUClast for PF-03084014 on Day 15 (n=1)1770 ± NA
AUCinf for nab-paclitaxel on Day 1 (n=3)5774 ± 11
AUClast for nab-paclitaxel on Day 1 (n=3)5185 ± 9
AUCinf for nab-paclitaxel on Day 15 (n=1)5050 ± NA
AUClast for nab-paclitaxel on Day 15 (n=1)4600 ± NA
AUCinf for gemcitabine on Day 1 (n=3)5316 ± 172
AUClast for gemcitabine on Day 1 (n=3)5262 ± 176
AUCinf for gemcitabine on Day 15 (n=1)2510 ± NA
AUClast for gemcitabine on Day 15 (n=1)2500 ± NA
SecondaryArea Under the Concentration-time Curve (AUC) for PF-03084014, Nab-P and Gemcitabine in Phase 2

AUC included AUC from time 0 extrapolated to infinite time (AUCinf), AUC from time 0 to end of dosing interval (AUCtau), and AUC from time 0 to last measured concentration (AUClast).

Time frame:
Cycle 1 Day 1 till end of last cycle

No measurements were reported for this outcome.

SecondaryMaximum Observed Plasma Concentration (Cmax) for PF-03084014, Nab-P and GEM in Phase 1
Time frame:
PF-03084014: Cycle 1 Days 3, 15, 22; Day 1 of subsequent cycles; and end of treatment. nab-P: Cycle 1 Days 1-3 and 15-17. Gemcitabine: Cycle 1 Days 1 and 15.
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) for PF-03084014, Nab-P and GEM in Phase 1
nanogram/milliliter (ng/mL)PF-03084014 + Nab-Paclitaxel + Gemcitabine
Cmax for PF-03084014 on Day 3 (n=3)527.3 ± 710
Cmax for PF-03084014 on Day 15 (n=1)943.0 ± NA
Cmax for nab-paclitaxel on Day 1 (n=3)6023 ± 6
Cmax for nab-paclitaxel on Day 15 (n=1)5140 ± NA
Cmax for gemcitabine on Day 1 (n=3)10760 ± 212
Cmax for gemcitabine on Day 15 (n=1)3620 ± NA
SecondaryMaximum Observed Plasma Concentration (Cmax) for PF-03084014, Nab-P and GEM in Phase 2
Time frame:
Cycle 1 Day 1 till end of last cycle

No measurements were reported for this outcome.

SecondarySystemic Clearance (CL) of Nab-paclitaxel in Phase 1
Time frame:
Cycle 1 Days 1-3, and 15-17
Reported as:
Geometric mean · liter (L)/hour (hr)
Systemic Clearance (CL) of Nab-paclitaxel in Phase 1
liter (L)/hour (hr)PF-03084014 + Nab-Paclitaxel + Gemcitabine
Day 1 (n=3)37.88 ± 25
Day 15 (n=1)38.60 ± NA
SecondarySystemic Clearance (CL) of Gemcitabine in Phase 1
Time frame:
Cycle 1 Days 1 and 15
Reported as:
Geometric mean · liter (L)/minute (min)
Systemic Clearance (CL) of Gemcitabine in Phase 1
liter (L)/minute (min)PF-03084014 + Nab-Paclitaxel + Gemcitabine
Day 1 (n=3)5.434 ± 165
Day 15 (n=1)8.160 ± NA
SecondarySystemic Clearance (CL) of PF-03084014, Nab-P and GEM in Phase 2
Time frame:
Cycle 1 Day 1 till end of last cycle

No measurements were reported for this outcome.

SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) for PF-03084014, Nab-P and GEM in Phase 1
Time frame:
PF-03084014: Cycle 1 Days 3, 15, 22; Day 1 of subsequent cycles; and end of treatment. nab-P: Cycle 1 Days 1-3 and 15-17. Gemcitabine: Cycle 1 Days 1 and 15.
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-03084014, Nab-P and GEM in Phase 1
hoursPF-03084014 + Nab-Paclitaxel + Gemcitabine
Tmax of PF-03084014 on Day 3 (n=3)1.23 (0.517 to 4.13)
Tmax of PF-03084014 on Day 15 (n=1)0.900 (NA to NA)
Tmax of nab-paclitaxel on Day 1 (n=3)0.550 (0.517 to 0.583)
Tmax of nab-paclitaxel on Day 15 (n=1)0.217 (NA to NA)
Tmax of gemcitabine on Day 1 (n=3)0.517 (0.250 to 0.533)
Tmax of gemcitabine on Day 15 (n=1)0.350 (NA to NA)
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) for PF-03084014, Nab-P and GEM in Phase 2
Time frame:
Cycle 1 Day 1 till end of last cycle

No measurements were reported for this outcome.

SecondaryVolume of Distribution at Steady State (Vss) for Nab-P and GEM in Phase 1
Time frame:
Cycle 1 (Days 1 and 15 for gemcitabine; Days 1-3 and 15-17 for nab-paclitaxel)
Reported as:
Geometric mean · liters
Volume of Distribution at Steady State (Vss) for Nab-P and GEM in Phase 1
litersPF-03084014 + Nab-Paclitaxel + Gemcitabine
Vss of nab-paclitaxel on Day 1 (n=3)64.46 ± 6
Vss of nab-paclitaxel on Day 15 (n=1)60.80 ± NA
Vss of gemcitabine on Day 1 (n=3)61.76 ± 186
Vss of gemcitabine on Day 15 (n=1)201.0 ± NA
SecondaryVolume of Distribution at Steady State (Vss) for PF-03084014, Nab-P and GEM in Phase 2
Time frame:
Cycle 1 Day 1 till end of last cycle

No measurements were reported for this outcome.

SecondaryPlasma Decay Half-life (t1/2) for Nab-P and GEM in Phase 1
Time frame:
Cycle 1 (Days 1 and 15 for gemcitabine; Days 1-3 and 15-17 for nab-paclitaxel)
Reported as:
Mean · hours
Plasma Decay Half-life (t1/2) for Nab-P and GEM in Phase 1
hoursPF-03084014 + Nab-Paclitaxel + Gemcitabine
t1/2 of nab-paclitaxel on Day 1 (n=3)2.500 ± 0.26851
t1/2 of nab-paclitaxel on Day 15 (n=1)2.030 ± NA
t1/2 of gemcitabine on Day 1 (n=3)0.2813 ± 0.14838
t1/2 of gemcitabine on Day 15 (n=1)0.2230 ± NA
SecondaryPlasma Decay Half-life (t1/2) for PF-03084014, Nab-P and GEM in Phase 2
Time frame:
Cycle 1 Day 1 till end of last cycle

No measurements were reported for this outcome.

SecondaryNumber of Participants With Objective Response (OR) in Phase 1

Number of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than (\<) 10 mm). No new lesions. PR was defined as more than or equal to (\>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
Screening till 28-35 days post last administration of study drug
Reported as:
Number · participants
Number of Participants With Objective Response (OR) in Phase 1
participantsPF-03084014 + Nab-Paclitaxel + Gemcitabine
Number of Participants With Objective Response (OR) in Phase 10
SecondaryNumber of Participants With Objective Response (OR) in Phase 2

Number of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria In Solid Tumors (RECIST). CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than (\<) 10 mm). No new lesions. PR was defined as more than or equal to (\>=) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
Screening till 28-35 days post last administration of study drug

No measurements were reported for this outcome.

SecondaryDuration of Response (DR) for Phases 1 and 2

Duration of response (DR) defined as the difference in days between the first date criteria for progression occurred or the participant died due to any cause and the first date that criteria for a PR or CR were met. DR calculated as (months) = (progression/death date - first date of OR + 1) divided by 30.4. CR: disappearance of all target lesions. PR: at least 30% decrease in the sum of diameters of target lesions.

Time frame:
Baseline, every 8 weeks until disease progression or unacceptable toxicity (up to 5 years)

No measurements were reported for this outcome.

Secondary1-year and 2-year OS in Phase 2

Overall survival was the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact.

Time frame:
From start of study treatment, collected every 3 months until death (up to 5 years)

No measurements were reported for this outcome.

SecondaryProgression-free Survival (PFS) in Phase 2

PFS was defined as the time from the date of first dose to the date of the first documentation of objective tumor progression or death on study due to any cause, whichever occurred first. PFS (in months) was calculated as (first event date - date of randomization +1) divided by 30.4.

Time frame:
From start of study treatment, collected every 3 months until death (up to 5 years)

No measurements were reported for this outcome.

SecondaryBrief Pain Inventory-Short Form (BPI-sf) Score - Phase 2

BPI-sf is an 11-item self-report questionnaire that is designed to assess the severity and impact of pain on daily functions. BPI-sf are 4 questions that assess pain intensity (worst, least, average, right now) and 7 questions that assess impact of pain on daily functions (general activity, mood, walking ability, normal work, relations with other people, sleep, enjoyment of life). Each question is answered on a scale ranging from 0 to 10; '0=No pain and 10=Pain as bad as you can imagine'. Measure can be scored by item, with lower scores being indicative of less pain or pain interference.

Time frame:
Day 1 of Cycle 1 and subsequent cycles; end of treatment

No measurements were reported for this outcome.

SecondaryChange From Baseline in European Quality of Life Questionnaire (EQ-5D) - Phase 2

EQ-5D: 6-item participant rated questionnaire to assess health-related quality of life in terms of a single utility score. There were 2 components: a Health State Profile and a Visual Analog Scale. Published weights are available that allow for the creation of a single summary score. Overall scores range from 0-1, with low scores representing a higher level of dysfunction.

Time frame:
Baseline till end of treatment

No measurements were reported for this outcome.

SecondaryEuropean Organization for Research and Treatment of Cancer, Quality of Life Questionnaire (EORTC QLQ-C30) - Phase 2

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.

Time frame:
Baseline till end of treatment

No measurements were reported for this outcome.

Adverse events

Collected over Baseline through and including 28 calendar days after the last administration of the investigational product.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-03084014+Nab-Paclitaxel+Gemcitabine—2/3 (66.7%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventPF-03084014+Nab-Paclitaxel+Gemcitabine
VomitingGastrointestinal disorders1/3
Alanine aminotransferase increasedInvestigations1/3
Aspartate aminotransferase increasedInvestigations1/3
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/3
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPF-03084014+Nab-Paclitaxel+Gemcitabine
FatigueGeneral disorders3/3
NauseaGastrointestinal disorders2/3
VomitingGastrointestinal disorders2/3
Alanine aminotransferase increasedInvestigations2/3
Aspartate aminotransferase increasedInvestigations2/3
AscitesGastrointestinal disorders1/3
ChillsGeneral disorders1/3
Mucosal inflammationGeneral disorders1/3
Candida infectionInfections and infestations1/3
FallInjury, poisoning and procedural complications1/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)PF-03084014+Nab-Paclitaxel+Gemcitabine
Mean64.3 ± 4.7
Sex: Female, Male
Sex: Female, Male(Participants)PF-03084014+Nab-Paclitaxel+Gemcitabine
Female2
Male1
08

Study locations

5 sites
  • Anschutz Inpatient Pavilion
    Aurora, Colorado 80045, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • University of Colorado Denver, CTO (CTRC)
    Aurora, Colorado 80045, United States
  • University of Rochester Investigational Drug Pharmacy
    Rochester, New York 14642, United States
  • University of Rochester
    Rochester, New York 14642, United States
09

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2014 to primary completion in Nov 2014, 2 months.

Results were first posted in Jun 2017, 2 years 7 months after primary completion. A results delay was requested in Dec 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2014
First posted
Apr 9, 2014
StartActual
Sep 3, 2014
Primary completionActual
Nov 6, 2014
CompletionActual
Nov 6, 2014
Results delay requested
Dec 7, 2015
Results first posted
Jun 12, 2017
Last update
Jan 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02109445
Lead sponsor
Pfizer
Collaborators
Academic GI Cancer Consortium (AGICC)
Responsible party
Sponsor
First posted
Apr 9, 2014
Start date
Sep 3, 2014
Primary completion
Nov 6, 2014
Completion
Nov 6, 2014
Results posted
Jun 12, 2017
Last update
Jan 10, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirogacestat

Start the discussion